Experimental Alzheimer's drug fails to deliver in closely watched clinical trial

Share this article:

Alzheimer's researchers met with disappointment Monday when officials from Pfizer announced that the experimental drug bapineuzumab failed to improve dementia symptoms in a Phase 3 trial.

Lead investigator Reisa Sperling, M.D., told the New York Times that the experimental drug showed “no evidence at all of a clinical benefit of treatment on either of the primary measures, one cognitive and one functional,” compared to placebo. Three drug makers were jointly developing bapineuzumab: Pfizer, Elan and Johnson & Johnson

Scientists told the paper that bapineuzumab's failure, in addition to other recent drug failures, has raised doubts about whether beta- amyloid plaques — proteins in the brain that have been targeted by drug developers — are implicated in the progressive disease.

Earlier trials suggested that bapineuzumab is more successful in Alzheimer's patients a specific gene, called ApoE4, which raises the risk a person will get Alzheimer's disease and can make the disease worse. Trial results testing bapineuzumab in this population will conclude within the next couple months, according to the paper.

Share this article:

More in News

Large hepatitis outbreak reaches 47 cases, podiatry company denies ManorCare's charges

The number of people infected in an infamous North Dakota Hepatitis C outbreak has risen, state health officials say.

National Quality Forum supports quality measures in bill to standardize post-acute assessments

National Quality Forum supports quality measures in bill ...

The National Quality Forum has come out in strong support of a proposed standardized quality measures, such as skin integrity, across different types of post-acute care settings. Uniform assessments are ...

CMS changes mind on hospice drugs

The Centers for Medicaid & Medicare Services has revised guidance on authorization of hospice drugs for those under Medicare Advantage and Part D plans, according to a new memo.